BioSpace News Archive

Policy

Federal judge enters consent decree against Delta Pharma

Mississippi compounder prohibited from manufacturing and distributing violative drug products

June 8, 2018
·
3 min read
Khiron to Open TSX Venture Exchange and Host Media Interviews on June 11, 2018

Khiron life Sciences Corp. will open the market of the TSX Venture Exchange on Monday, June 11, 2018 at 9:30 a.m. EDT.

June 8, 2018
·
3 min read
Vetter Strikes out on New Pathways to Further Develop the Injection Process

How can digital trends be used purposefully in regards to the application of injection systems? That is the key question being addressed by Vetter’s Open Innovation Challenge.

June 8, 2018
·
4 min read
Genetown

Fluid Imaging Technologies Wins Innovator of the Year Award from Manufacturers Association of Maine

Fluid Imaging Technologies, Inc. was recognized and honored with the Innovator of the Year award at the Manufacturers Association of Maine (MAMe) annual summit, which took place on Friday, June 1.

June 8, 2018
·
2 min read
Business

First Ketamine Infusion Clinic in Palm Springs, CA Opens

Offering an innovative treatment for mood and pain disorders.

June 8, 2018
·
2 min read
Pharm Country

NeoTract Announces Independent Analysis in UK Confirming Cost Effectiveness of UroLift® System Treatment for Benign Prostatic Hyperplasia (BPH)

Study from Imperial College Health Partners Demonstrates Substantial Economic and Quality of Life Benefits of UroLift System Over Transurethral Resection of the Prostate

June 8, 2018
·
5 min read
Business

Autolus Announces Appointment of Andrew J. Oakley as Senior Vice President and Chief Financial Officer

Effective prior to the closing of Autolus’ planned initial public offering.

June 8, 2018
·
2 min read
Job Trends

Healthcare Trust of America, Inc. Announces Stock Repurchase Program

Board of Directors approved a stock repurchase program authorizing the Company to purchase up to $100 million of its Class A common stock from time to time prior to June 7, 2020.

June 8, 2018
·
5 min read
Drug Development

Alnylam Reports Updated Positive Results from Phase 1/2 Study of Lumasiran in Patients with Primary Hyperoxaluria Type 1 (PH1)

Patients Receiving Investigational Lumasiran Experienced Substantial and Sustained Reductions in Urinary Oxalate, Confirming Potential for RNAi-Mediated Inhibition of Glycolate Oxidase as a Robust Therapeutic Approach for PH1

June 8, 2018
·
11 min read
Pharm Country

PAVmed to Receive $10.4 Million in Gross Proceeds from Oversubscribed Rights Offering

Equity subscription rights offering expired at 5:00 p.m. Eastern Time on Thursday, June 7, 2018 and, as such, the rights are no longer exercisable

June 8, 2018
·
6 min read